P120 Characteristics and safety outcomes of rheumatoid arthritis patients treated with Amgevita® in the UK using data from a national register
Bibliographic record
Abstract
Abstract Background/Aims Rheumatoid arthritis (RA) is a chronic inflammatory disease that can cause joint damage and impair quality of life. Research advances have led to seven adalimumab (ADL) biosimilars approved in the EU, making it crucial to understand their long-term benefit-risk profiles. This study aims to 1) estimate the clinical characteristics, serious adverse events (SAEs), and outcomes in patients with RA exposed to Amgevita® and 2) to estimate the incidence rates for the same outcomes from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRB-RRA) antitumor necrosis factor (TNF) comparison cohort. Methods Results from a crude pharmacovigilance report sent to Amgen on a subset of all Amgevita patients in the BSRBR-RA are presented. The BSRBRRA is a nationwide prospective study for patients with RA receiving biologic treatments, including anti-TNF inhibitors (i.e., adalimumab) and non-TNF biologics, that seeks to evaluate the long-term toxicity of these agents in clinical practice. Eligible participants were men and women ≥16 years of age with RA who registered in the study within 6 months of initiating Amgevita to comprise study cohort (these patients represent one-third of all Amgevita patients recruited into the BSRBR-RA). Descriptive characteristics were calculated for all variables of interest. Summary statistics for continuous variables include the number of patients, mean, median, SD or standard error, minimum, and maximum. Results From 01/01/2019 to 31/03/2022, 307 RA patients treated with Amgevita were enrolled in the registry. The follow-up period for this cohort ended 30/11/2023. The mean (SD) age of the population was 59.7 (12.0) years, 86 (28.0%) of patients identified as male, and mean (SD) disease duration at initiation was 9.9 (9.8) years. Two-thirds of Amgevita patients were biologically naïve and 9.8% were using steroids at Amgevita initiation. Non-adjusted incident rates of SAEs per 1,000 patient years by patient cohort are presented in Table 1. Conclusion These results show crude safety incidence rates for Amgevita patients in the BSRBR-RA, with point estimates similar to the anti-TNF cohort, though the confidence intervals are large due to small patient numbers. Ongoing monitoring of biosimilars is essential to optimize RA treatment and patient care. Disclosure A.E. Servin: Corporate appointments; Amgen. Shareholder/stock ownership; Amgen. M. Lillie: Corporate appointments; Amgen. Shareholder/stock ownership; Amgen. L.C. Coates: Consultancies; AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer, Takeda, UCB. Grants/research support; AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, UCB. M. Brunori: Corporate appointments; Amgen. Shareholder/stock ownership; Amgen. L. Krishnamoorthy: Corporate appointments; Amgen. Shareholder/stock ownership; Amgen. F. Humby: Consultancies; Roche, AbbVie, Genentech, UCB, Novartis. Honoraria; Roche, UCB, Novartis. Member of speakers’ bureau; UCB, Novartis.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.009 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.004 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".